Figures & data
Figure 1 Model structure. The model represents a 1-month cycle. Patients may receive AS or oral AAPs in each cycle. Treatment decisions that apply to a cycle do not impact subsequent cycles. Patients who discontinue on AS in a given cycle may receive AS in the subsequent cycle. At the end of each cycle, clinical (hospitalization and PANSS and CGI-S score) and health economic outcomes (costs and utilities) are estimated for the cohort of patients.
![Figure 1 Model structure. The model represents a 1-month cycle. Patients may receive AS or oral AAPs in each cycle. Treatment decisions that apply to a cycle do not impact subsequent cycles. Patients who discontinue on AS in a given cycle may receive AS in the subsequent cycle. At the end of each cycle, clinical (hospitalization and PANSS and CGI-S score) and health economic outcomes (costs and utilities) are estimated for the cohort of patients.](/cms/asset/bdab65e4-c745-4862-b4ac-36de3dfcec45/dceo_a_12157758_f0001_c.jpg)
Table 1 PANSS Score at Baseline, 3 Months, and 6 Months of Treatment with AS
Table 2 Health Care Resource Utilization and Costs
Table 3 Cost-Effectiveness of AS versus Generic Oral AAPs Estimated Using PANSS Scores and Treatment Status (Base Case)
Figure 2 Uncertainties in the top five factors influencing ICER over 12 months from the payer perspective (deterministic sensitivity analysis).
![Figure 2 Uncertainties in the top five factors influencing ICER over 12 months from the payer perspective (deterministic sensitivity analysis).](/cms/asset/02050232-09bd-4b75-a889-190bfcf5ceea/dceo_a_12157758_f0002_c.jpg)
Figure 3 Scatterplot evaluating the influence of uncertainties on the ICER over 12 months from the payer perspective (probabilistic sensitivity analysis).
![Figure 3 Scatterplot evaluating the influence of uncertainties on the ICER over 12 months from the payer perspective (probabilistic sensitivity analysis).](/cms/asset/97c0d726-8923-4d14-9e90-9398bddca6ec/dceo_a_12157758_f0003_c.jpg)
Table 4 Cost-Effectiveness of AS versus Generic Oral AAPs Using Durability of Treatment Effect Assumption (Scenario Analysis)